Epigenetics of cardiomyopathies: the next frontier
Heart Failure Reviews · 26.11.2024 · 30 (1) · 257-270
DOI: 10.1007/s10741-024-10460-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Heart Failure Reviews, online erschienen am 26.11.2024. Verfasst von Aida Hajdarpašić und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biology and Genetics, Sarajevo Medical School, University Sarajevo School of Science and Technology, Hrasnička Cesta 3a, 71210,…. Hauptthemen laut MEDLINE: Cardiomyopathies, Epigenesis, Genetic, DNA Methylation. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cardiomyopathies (CMP) are a diverse group of myocardial diseases that cause structural, functional, and pathological changes to the heart. Alterations at the molecular level associated with the clinical phenotype and progression of CMPs cannot be solely explained by the genetic mutations, even in inherited cardiomyopathies. Epigenetics and environmental factors are likely to significantly modify the clinical manifestations of CMPs, resulting in variable clinical expression and different age-related penetrance. This review examines the role of dysfunctional DNA methylation, histone modifications, chromatin remodelling, and noncoding RNAs in the development and exacerbation of CMPs, highlighting their potential as diagnostic markers and therapeutic targets, including the use of histone deacetylase inhibitors. Additionally, it explores how environmental exposures can influence epigenetic changes and potentially be used for preventive strategies and personalized care in CMP patients. Monozygotic twin studies and intergenerational studies are discussed as valuable tools for understanding the interplay between genetics, epigenetics, and environmental factors. Lastly, this review addresses current challenges and future perspectives, such as the need for greater specificity in epigenetic therapies, minimizing off-target effects, and investigating sex differences in CMP research and treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Biology and Genetics, Sarajevo Medical School, University Sarajevo School of Science and Technology, Hrasnička Cesta 3a, 71210, Sarajevo, Ilidža, Bosnia and Herzegovina. aida.hajdarpasic@ssst.edu.b…
- Thoraxcenter, Department of Cardiology, Cardiovascular Institute. Erasmus MC - University Medical Center Rotterdam, Office RG-431Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.
- Department of Clinical Genetics, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
- Thoraxcenter, Department of Cardiology, Cardiovascular Institute. Erasmus MC - University Medical Center Rotterdam, Office RG-431Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands. k.caliskan@erasmusmc.nl.
ORCID-Profile: Aida Hajdarpašić, Martijn Tukker, Wouter Te Rijdt, Sharida Mohamedhoesein, Wouter C Meijers, Kadir Caliskan
Zitieren
APA
Hajdarpašić, A., Tukker, M., Rijdt, W. T., Mohamedhoesein, S., Meijers, W. C., & Caliskan, K. (2024). Epigenetics of cardiomyopathies: the next frontier. Heart Failure Reviews, 30(1), 257-270. https://doi.org/10.1007/s10741-024-10460-4
Vancouver
Hajdarpašić A, Tukker M, Rijdt WT, Mohamedhoesein S, Meijers WC, Caliskan K. Epigenetics of cardiomyopathies: the next frontier. Heart Failure Reviews. 2024;30(1):257-270. doi:10.1007/s10741-024-10460-4
BibTeX
@article{Hajdarpai2024,
author = {Hajdarpašić, Aida and Tukker, Martijn and Rijdt, Wouter Te and Mohamedhoesein, Sharida and Meijers, Wouter C and Caliskan, Kadir},
title = {Epigenetics of cardiomyopathies: the next frontier},
journal = {Heart Failure Reviews},
year = {2024},
volume = {30},
number = {1},
pages = {257--270},
doi = {10.1007/s10741-024-10460-4}
}
EUVIMED